After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)

NeoGenomics (NEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • Feb 20, 2026

NeoGenomics to Participate in Upcoming Investor Conferences

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.

Business Wire • Feb 18, 2026

NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript

NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 17, 2026

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.

Business Wire • Feb 17, 2026

NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates

NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago.

Zacks Investment Research • Feb 17, 2026

NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro

NEO launches PanTracer Pro, a pan-solid tumor assay built to streamline genomic testing and speed treatment decisions in advanced cancers.

Zacks Investment Research • Feb 16, 2026

NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.

Business Wire • Feb 12, 2026

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.

Business Wire • Jan 27, 2026

NeoGenomics: Distribution Moat In Community Oncology

NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO's clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration.

Seeking Alpha • Jan 25, 2026

NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026